BioCentury | Dec 15, 2017
Finance

Fewer, further

...AmorChem’s spinouts include cancer company SpecificiT Pharma Inc., ophthalmology play SemaThera Inc. and inflammation companies Mperia Therapeutics Inc....
BioCentury | Dec 8, 2017
Financial News

AmorChem raises C$44.2M toward second fund

...also named Maxime Ranger general partner. Ranger is president and CEO of AmorChem portfolio company Mperia Therapeutics Inc....
...fund in 2011 at C$41.3 million ($32.5 million). AmorChem Group, Montreal, Quebec Allison Johnson AmorChem Merck & Co. Inc. Mperia Therapeutics Inc....
BioCentury | Dec 6, 2017
Financial News

AmorChem raises C$44.2M towards second fund

...also named Maxime Ranger general partner. Ranger is president and CEO of AmorChem portfolio company Mperia Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Dec 15, 2017
Finance

Fewer, further

...AmorChem’s spinouts include cancer company SpecificiT Pharma Inc., ophthalmology play SemaThera Inc. and inflammation companies Mperia Therapeutics Inc....
BioCentury | Dec 8, 2017
Financial News

AmorChem raises C$44.2M toward second fund

...also named Maxime Ranger general partner. Ranger is president and CEO of AmorChem portfolio company Mperia Therapeutics Inc....
...fund in 2011 at C$41.3 million ($32.5 million). AmorChem Group, Montreal, Quebec Allison Johnson AmorChem Merck & Co. Inc. Mperia Therapeutics Inc....
BioCentury | Dec 6, 2017
Financial News

AmorChem raises C$44.2M towards second fund

...also named Maxime Ranger general partner. Ranger is president and CEO of AmorChem portfolio company Mperia Therapeutics Inc....
Items per page:
1 - 3 of 3